The RBF strategy has successfully produced fungal mycelial biomass and EPS in a very strictly regulated manner at high productivity rates compared to batch fermentation. The problematic lag phase and seed culture preparation were reduced in length; harvesting volume doubled, yield of product increased, and medium consumption was reduced in an RBF relative to batch. 80% broth replacement volume and transition phase were optimised. Dispersed mycelial filaments with ovoid-shaped pellets are the typical morphological characteristics associated with EPS production. N-limiting medium in an unbaffled 2.5-L bioreactor stimulated EPS formation during RBF compared to in baffled condition. The current study has managed to alter the molecule's hydrophobicity thus making it water-soluble as proved by compositional analysis and spectroscopy. The sulphated derivative of native glucan was identified as (1, 3)-β-D-glucan. Sulphation was an effective approach to improve antibacterial, antifungal, antiproliferative and immunomodulatory (NO stimulation) activity of the sulphated (1,3)-β-D-glucan or GS. GS maybe safe in in vitro trials due to its demonstrated lack of toxicity towards a normal human prostate cell line (PN2TA). GS also showed antimicrobial-antifungal-immunomodulatory activities derived from a single compound. Fungal cells tended to grow well in the porous structure of PUF cubes and the RBF using immobilised fungal cells was an efficient method for production of β-glucan with a high yield. This study could be beneficial for other medicinal mushroom fermentation.
|Date of Award||29 Mar 2016|
- University Of Strathclyde
|Supervisor||Brian McNeil (Supervisor) & Linda Harvey (Supervisor)|